AAPL339.31-3.63 (-1.06%) ▼|ABBV288.39+5.71 (+2.02%) ▲|ABT102.70-1.36 (-1.31%) ▼|ACN239.21+2.28 (+0.96%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.62+0.59 (+0.32%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.41+2.00 (+0.63%) ▲|BA190.39-1.03 (-0.54%) ▼|BAC50.66+0.27 (+0.54%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.55+3.95 (+0.35%) ▲|BMY61.72+2.89 (+4.90%) ▲|BNY144.26+1.82 (+1.27%) ▲|BRK-B540.18+7.95 (+1.49%) ▲|C122.53+0.84 (+0.69%) ▲|CAT725.47-0.32 (-0.04%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.58+1.75 (+0.88%) ▲|COP145.97+0.73 (+0.50%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.44-0.01 (0.00%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.71+2.03 (+2.19%) ▲|CVX225.78+1.41 (+0.63%) ▲|DE632.54+5.54 (+0.88%) ▲|DHR224.02-0.41 (-0.18%) ▼|DIS111.66+2.07 (+1.88%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.48-0.07 (-0.04%) ▼|FDX298.76+4.98 (+1.69%) ▲|GD344.48+3.05 (+0.89%) ▲|GE299.92-11.36 (-3.65%) ▼|GEV890.50-17.94 (-1.97%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.10-5.65 (-6.83%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.99+9.21 (+1.05%) ▲|HD315.16+5.28 (+1.70%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM242.02+5.63 (+2.38%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.42+5.63 (+2.22%) ▲|JPM335.45+1.92 (+0.58%) ▲|KO93.51+0.09 (+0.09%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,284.88+44.54 (+3.59%) ▲|LMT548.87+0.64 (+0.12%) ▲|LOW198.58+2.66 (+1.36%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.52+4.12 (+0.67%) ▲|MCD246.54+3.87 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.67+1.90 (+2.05%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.44+9.43 (+5.82%) ▲|MO74.63+0.54 (+0.73%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.43+1.96 (+1.10%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.89+0.72 (+0.92%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.89+0.68 (+1.83%) ▲|NOW149.58+4.22 (+2.90%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.09+1.50 (+1.16%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.13+0.69 (+2.34%) ▲|PG159.38+1.69 (+1.07%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.93-1.12 (-0.56%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.83+8.45 (+1.24%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|AAPL339.31-3.63 (-1.06%) ▼|ABBV288.39+5.71 (+2.02%) ▲|ABT102.70-1.36 (-1.31%) ▼|ACN239.21+2.28 (+0.96%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.62+0.59 (+0.32%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.41+2.00 (+0.63%) ▲|BA190.39-1.03 (-0.54%) ▼|BAC50.66+0.27 (+0.54%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.55+3.95 (+0.35%) ▲|BMY61.72+2.89 (+4.90%) ▲|BNY144.26+1.82 (+1.27%) ▲|BRK-B540.18+7.95 (+1.49%) ▲|C122.53+0.84 (+0.69%) ▲|CAT725.47-0.32 (-0.04%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.58+1.75 (+0.88%) ▲|COP145.97+0.73 (+0.50%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.44-0.01 (0.00%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.71+2.03 (+2.19%) ▲|CVX225.78+1.41 (+0.63%) ▲|DE632.54+5.54 (+0.88%) ▲|DHR224.02-0.41 (-0.18%) ▼|DIS111.66+2.07 (+1.88%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.48-0.07 (-0.04%) ▼|FDX298.76+4.98 (+1.69%) ▲|GD344.48+3.05 (+0.89%) ▲|GE299.92-11.36 (-3.65%) ▼|GEV890.50-17.94 (-1.97%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.10-5.65 (-6.83%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.99+9.21 (+1.05%) ▲|HD315.16+5.28 (+1.70%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM242.02+5.63 (+2.38%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.42+5.63 (+2.22%) ▲|JPM335.45+1.92 (+0.58%) ▲|KO93.51+0.09 (+0.09%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,284.88+44.54 (+3.59%) ▲|LMT548.87+0.64 (+0.12%) ▲|LOW198.58+2.66 (+1.36%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.52+4.12 (+0.67%) ▲|MCD246.54+3.87 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.67+1.90 (+2.05%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.44+9.43 (+5.82%) ▲|MO74.63+0.54 (+0.73%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.43+1.96 (+1.10%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.89+0.72 (+0.92%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.89+0.68 (+1.83%) ▲|NOW149.58+4.22 (+2.90%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.09+1.50 (+1.16%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.13+0.69 (+2.34%) ▲|PG159.38+1.69 (+1.07%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.93-1.12 (-0.56%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.83+8.45 (+1.24%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|
19.1 C
New York
Tuesday, October 20, 2026

Tag: cell

newsFORsourcecompanycontentinformation1releasesmarket

Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, Aug. 7, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a...

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2025, and provide a corporate update on August 14, 2025, at 8:30 a.m. Eastern Time.

Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of 2025 Initiated ALKAZAR...

US NCI Sponsors Senhwa Biosciences’ Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma

TAIPEI and SAN DIEGO, Aug. 7, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for...

Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®

AHMEDABAD, India, Aug. 7, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as...

General Motors and Hyundai Motor Company Announce Plans for First Five Co-developed Vehicles

Co-development work underway for vehicles to launch in 2028Jointly developed next-generation commercial van to be introduced in North AmericaDETROIT and SEOUL, Aug. 6, 2025...

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

Crown Castle Declares Quarterly Common Stock Dividend

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

SUNNYVALE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended June 30, 2025 by conference call on Monday, August 11, 2025 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session.

Intellectuals Respond to CT Group’s Heartfelt Call for National Development

TAIPEI, Taiwan, Aug. 06, 2025 (GLOBE NEWSWIRE) -- “More than ever, this is the moment for the intellect and efforts of Vietnamese, both domestic and abroad, to prove that we can achieve what once seemed impossible.” This heartfelt call from CT Group’s Chairman resonated throughout the "Vietnam Dreams Come True" conference held on July 25, 2025, in Taiwan, inspiring a community of intellectuals, experts, and overseas Vietnamese living, studying, and working abroad.

Immix Biopharma Announces Other Serious Diseases Strategy

– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) –

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCell

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers